Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 23823695)

1.

Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.

Jin H, Xiong Y, Sun J, Zhang Y, Huang F, Zhou H, Fan Z, Xu D, Wei Y, Dai M, Feng R, Liu Q.

PLoS One. 2013 Jun 18;8(6):e65981. Print 2013.

2.

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A.

Leukemia. 2003 Feb;17(2):290-7.

PMID:
12592325
3.

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.

Bone Marrow Transplant. 2005 Mar;35(6):601-8.

PMID:
15756285
4.
5.

Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).

Cummins M, Cwynarski K, Marktel S, Dazzi F, Cavenagh J, Clark RE, Holyoake TL, Milligan D, Parker A, Russell NH, Marks DI; Clinical Trials Committee British Society of Blood & Marrow Transplantation (BSBMT).

Bone Marrow Transplant. 2005 Dec;36(12):1065-9.

PMID:
16247434
6.

Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.

Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS.

Biol Blood Marrow Transplant. 2004 Mar;10(3):171-7.

PMID:
14993882
7.

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.

PMID:
14993886
8.

Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.

Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ.

Bone Marrow Transplant. 2005 Dec;36(11):1009-15.

PMID:
16205732
9.

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.

Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL.

Biol Blood Marrow Transplant. 2010 May;16(5):639-46. doi: 10.1016/j.bbmt.2009.11.026. Epub 2010 Feb 4.

10.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

11.

A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.

Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ.

Haematologica. 2006 May;91(5):663-6. Epub 2006 Apr 19.

12.

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.

13.

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.

Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.

J Clin Oncol. 1999 Feb;17(2):561-8.

PMID:
10080600
15.

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V; EBMT Acute Leukemia Working Party.

J Clin Oncol. 2007 Nov 1;25(31):4938-45. Epub 2007 Oct 1.

16.

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T; Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT).

Leukemia. 2003 Sep;17(9):1707-12.

PMID:
12970768
17.

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.

Angstreich GR, Smith BD, Jones RJ.

Curr Opin Oncol. 2004 Mar;16(2):95-9. Review.

PMID:
15075898
18.

Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.

Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.

Bone Marrow Transplant. 1997 Oct;20(7):533-41.

19.

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.

Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, Goldman JM.

Blood. 2002 May 15;99(10):3861-2.

20.

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.

De Souza CA, Vigorito AC, Ruiz MA, Nucci M, Dulley FL, Funcke V, Tabak D, Azevedo AM, Byington R, Macedo MC, Saboya R, Penteado Aranha FJ, Oliveira GB, Zulli R, Martins Miranda EC, Azevedo WM, Lodi FM, Voltarelli JC, Simões BP, Colturato V, De Souza MP, Silla L, Bittencourt H, Piron-Ruiz L, Maiolino A, Gratwohl A, Pasquini R.

Haematologica. 2005 Feb;90(2):232-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk